Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy
26 September 2016
Number of times this article has been viewed

Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease primarily affecting synovial joints and is characterized by persistent high-grade systemic inflammation. Proinflammatory cytokines, particularly interleukin-6 (IL-6), are of crucial importance in the pathogenesis of the disease, driving both joint inflammation and extra-articular comorbidities. Tocilizumab, a humanized IL-6 receptor-inhibiting monoclonal antibody, has been the first, and, to date, the only, IL-6 inhibitor approved for the treatment of RA. Many studies have demonstrated the potency and effectiveness of tocilizumab in controlling disease activity and radiological progression of RA. These successful results have encouraged the development of novel IL-6 inhibitors, among which a promising agent is sirukumab (SRK), a human anti-IL-6 monoclonal antibody currently under evaluation in Phase II/III studies in patients with RA, systemic lupus erythematosus, giant-cell arteritis, and major depressive disorder. The evidence to date indicates SRK as an effective and well-tolerated new therapeutic tool for patients with active RA, with some preliminary data suggesting a specific beneficial impact on relevant systemic complications associated with the disease, such as depression and cardiovascular disease. Conversely, although pathophysiological considerations make plausible the hypothesis that IL-6 blockade with SRK may also be beneficial in the treatment of many diseases other than RA (either autoimmune or not), available clinical data in patients with systemic lupus erythematosus do not seem to support this view, also giving rise to potentially relevant concerns about drug safety. If large Phase III clinical trials currently in progress in patients with RA confirm the efficacy and tolerability of SRK, then in the long term, this drug could, in the near future, occupy a place in the treatment of the disease, potentially also opening the doors to a more extended use of SRK in a wide range of disorders in which IL-6 plays a key pathogenic role.

Keywords: sirukumab, rheumatoid arthritis, interleukin-6, tocilizumab, systemic lupus erythematosus, cardiovascular disease, interleukin-6

Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease affecting the synovial joints also leading to extra-articular manifestations, characterized by persistent high-grade systemic inflammation. Classical clinical presentation consists of a symmetrical polyarthritis, related to intense leukocyte infiltration, hyperplasia, and neovascularization of the synovial tissue, resulting in an inflammatory destruction of cartilage and subchondral bone. The disease affects 0.5%–1% of adults in developed countries, with a global prevalence ~0.25%, thus representing an important cause of disability and preterm mortality worldwide. Among the extra-articular manifestations, accelerated cardiovascular disease (CVD) represents the main driver of the 2× higher risk of death observed in these patients when compared to age- and sex-matched non-RA subjects.
Although the etiology of RA remains substantially unknown, it is well recognized that proinflammatory cytokines, particularly tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), are of crucial importance in the pathogenesis of the disease, driving both joint inflammation and extra-articular comorbidities. This evidence has led in the last 15 years to the development of drugs specifically inhibiting these cytokines, thus kicking off to the era of biologic drugs that have revolutionized the therapeutic approach to RA. Starting from early 2000s, TNF-α inhibitors were the first class of cytokine-targeting drugs introduced for RA therapy, followed by the IL-1 receptor antagonist anakinra. In 2010, the first, and to date the only, IL-6 inhibitor tocilizumab (TCZ), a humanized IL-6 receptor (IL-6R)-inhibiting monoclonal antibody, was approved for the treatment of modest-to-severe RA in patients who have failed other disease-modifying antirheumatic drugs (DMARDs), including biologics. A large body of evidence demonstrated the potency and effectiveness of TCZ in reducing the signs and symptoms, as well as radiological disease progression of RA, thus pointing to this drug as a mainstay in the current treatment of the disease. In the last years, these successful results have encouraged the development of novel biologic DMARDs targeting IL-6 or IL-6R, among which sirukumab (SRK), a human anti-IL-6 monoclonal antibody currently under evaluation in Phase III studies in patients with RA, is promising.

The aim of this paper is to review the evidence available to date supporting the future use of SRK in the treatment of RA in the light of the key role played by IL-6 in the pathogenesis of the disease, including both articular and extra-articular manifestations.

**Biology of IL-6**

IL-6 is a small (~25 kD) secreted glycoprotein composed of 184 amino acids and characterized by a four-helix bundle structure. It is produced by several cell types, including leukocytes (T- and B-lymphocytes, monocytes, macrophages), fibroblasts, osteoblasts, keratinocytes, endothelial cells, mesangial cells, adipocytes, skeletal myocytes, cardiomyocytes, brain cells (astroglia, microglia, neurons), and some tumor cells in response to various stimuli, such as lipopolysaccharide and other bacterial products, viruses, cytokines (TNF-α, IL-1, transforming growth factor [TGF]-β), adenosine triphosphate, parathormone, vitamin D3, homocysteine, and angiotensin II. Increases during inflammatory conditions, reaching concentrations in the range of µg/mL during sepsis. In fact, this cytokine critically contributes to host defense against infections and tissue injuries by stimulating acute-phase immune response and hematopoiesis, but it also regulates metabolic, regenerative, and neural processes under physiological conditions. Once released, IL-6 exerts its pleiotropic biological effects by activating a unique IL-6R signaling system, including the IL-6R and downstream signaling molecules.

**IL-6R**

The IL-6R is constituted by two chains: 1) an IL-6 binding chain or IL-6Rα, which exists in two forms, ie, a 80 kD transmembrane IL-6R (mIL-6R), and a 50–55 kD soluble IL-6R (sIL-6R) and 2) a 130 kD signal-transducing chain, named gp130 or IL-6Rβ. The mIL-6R is expressed on the surface of a limited number of cell types, ie, hepatocytes, megakaryocytes, and leukocytes, including monocytes, macrophages, neutrophils, and T- and B-lymphocytes. The sIL-6R is present in human plasma (25–75 ng/mL) and tissue fluids and can be generated by proteolytic cleavage (shedding) of the mIL-6R by metalloproteinases (ADAM), 10 and 17, or, in minor part, via alternative splicing by omission of the transmembrane domain. Conversely, gp130 is ubiquitously expressed on all human cells.

Upon biding to either mIL-6R or sIL-6R, IL-6 induces the homodimerization of the IL-6R/gp130 chains, resulting in the formation of a hexamer (comprising two IL-6, two IL-6R, and two gp130 proteins), which in turn triggers the downstream signaling cascade. Cellular activation via IL-6 binding to mIL-6R is named “classic signaling”. All other cells not expressing mIL-6R obtain their IL-6 signals by “trans-signaling”: IL-6 binds to the circulating sIL-6R, and this complex forms the signaling complex with gp130 on the cell surface. Trans-signaling can occur in a broad range of human cells, thus contributing to explain the pleiotropic activities of IL-6. Increasing evidence indicates that IL-6 trans-signaling, rather than classical signaling, is particularly involved in disease development. Although the picture is not completely clear, it is currently believed that homeostatic and regenerative activities of IL-6 are mediated by classical signaling, while proinflammatory effects mainly result from trans-signaling pathway activation. Interestingly, a soluble form of the gp130 (sgp130) was also detected in the circulation at relatively high concentrations, mainly produced by alternative splicing. Since sgp130 can
bind to the IL-6/sIL-6R complex, it acts as a natural and specific inhibitor of IL-6 mediated trans-signaling. Indeed, classic signaling is not affected by sgp130. Recently, a fusion protein consisting of the extracellular portion of gp130 fused to the Fc region of human IgG1 (sgp130Fc) was developed. By forming dimers, sgp130Fc acts as a potent inhibitor of IL-6 trans-signaling (> tenfold more potent than monomeric natural occurring sgp130 form). Although preclinical studies showed efficacy of sgp130Fc treatment in animal models of inflammatory arthritis, peritonitis, inflammatory bowel disease, and colon cancer, it is not still currently clear whether this approach actually preserves mIL-6R-mediated anti-inflammatory responses.

While IL-6R is a unique binding receptor for IL-6, the gp130 signal-transducing chain is shared by members of the IL-6 family, comprising leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, IL-11, cardiotrophin-1, neuropoietin-1, IL-27, and IL-35.  

### IL-6 signal transduction

After IL-6 binding, receptor homodimerization promotes the interaction between the gp130 chain with the tyrosine kinase JAK (Janus kinase), resulting in their mutual transactivation. In turn, JAK activation triggers three main intracellular signaling pathways, via phosphorylation of two key proteins, ie, 1) the Src Homology domain-containing protein thyrosin Phosphatase-2 (SHP-2), and 2) the signal transducer and activator of transcription proteins (STAT1–STAT3). Once phosphorylated, SHP-2 can, on one hand, interact with Grb2 (growth factor receptor bond protein 2), leading to the activation of the Ras/ERK/MAPK (rat sarcoma protein/ extracellular signal-regulated kinase/mitogen-activated protein kinase) cascade, and/or, on the other hand, can activate the PI3K/Akt (phosphoinositol-3 kinase/protein kinase B) pathway. On the contrary, phosphorylation of STATs proteins induces the formation of heterodimers (STAT1/STAT3) or homodimers (STAT1/STAT1 and/or STAT3/STAT3), which subsequently translocate into the nucleus. In all cases, the final result of the activation of these intracellular pathways is the induction of the transcription of multiple target genes accounting for the pleiotropic biological activities of IL-6.  

### Pleiotropic biological effects of IL-6

IL-6 exerts a wide range of biological activities, crucially implicated in the activation of the acute inflammatory response, as well as in the transition from innate to acquired immunity. Moreover, IL-6 has several additional roles in a variety of other processes, including metabolism, cognitive function, and embryonic development.

### Effects on the immuno-inflammatory response

When infections or tissue injuries of various origins occur, a systemic reaction named acute-phase response is rapidly induced to neutralize pathogens and prevent their further invasion, minimize tissue damage, and promote wound healing. The acute-phase response, consisting of fever and production of acute-phase proteins by hepatocytes, is chiefly driven by IL-6. In fact, IL-6 increases body temperature by acting on the neurons of the preoptic hypothalamic region involved in thermoregulation and stimulates the liver to synthesize acute-phase proteins, such as C-reactive protein (CRP), fibrinogen, complement component C3, serum amyloid A, hepcidin, haptoglobin, α1-acid glycoprotein, α1-antitrypsin, α1-antichymotrypsin, and ceruloplasmin, while albumin, transferrin, fibronectin, transthyretin, and retinol-binding protein (“negative” acute-phase proteins) production is inhibited. In addition, IL-6 promotes monocyte-to-macrophage differentiation, stimulates the maturation of myeloid precursors and megakaryocytes leading to neutrophilia and thrombocytosis, induces angiogenesis via vascular endothelial growth factor production, enhances lymphocyte and neutrophil trafficking by upregulating adhesion molecule expression on endothelial cells (particularly, the intracellular adhesion molecule-1 and the vascular cell adhesion molecule), increases antibody production by B lymphocytes, and potentiates the proliferation of T helper (T<sub>H</sub>) lymphocytes promoting their differentiation toward T<sub>H</sub>2 or T<sub>H</sub>17 cells. In all cases, these changes contribute, via different but synergistic mechanisms, to realize an integrated response finalized to host defense.

### Extra-immunoinflammatory effects

Besides its key involvement in the immune-inflammatory response, IL-6 also plays an important role under physiological conditions by modulating a number of multisystemic functions such as embryogenesis, glucose and lipid metabolism, bone remodeling, liver regeneration, neural tissue homeostasis, cognitive function, sleep, memory, pain, and emotional behavior. The knowledge of these extra-immunoinflammatory effects may help explain the pathogenesis of some systemic manifestations observed in RA and other chronic inflammatory diseases characterized by persistently elevated IL-6 levels.

In RA patients, the impact of this cytokine on metabolism and bone homeostasis may be of particular pathophysiological
and clinical interest. Adipose tissue considerably contributes to IL-6 production under physiological conditions, accounting for ~35% of circulating IL-6 levels. Moreover, during prolonged exercise, contracting skeletal muscle becomes a major source of IL-6, increasing its plasma levels up to 100-fold. IL-6 stimulates lipolysis (and inhibits lipogenesis) in adipocytes, and increases cholesterol and triglyceride uptake by peripheral tissues via enhancement of the very low-density lipoprotein receptor expression, promoting body weight loss and serum lipid levels reduction. In addition, IL-6 enhances insulin sensitivity in hepatocytes and muscle cells, improving glucose utilization and tolerance. Although these effects suggest that this cytokine may be part of a physiological mechanism underlying the exercise-induced increase of
insulin activity that enhances endurance, evidence indicates
that chronic elevation of IL-6 conversely leads to insulin
resistance in liver and adipose cells.\(^\text{19,26}\)

With regard to the impact on bone tissue, IL-6 affects
bone resorption and bone formation that are required for
skeletal development, growth, and maintenance, by regulat-
ing differentiation and activity of osteoblasts, osteoclasts,
and chondrocytes.\(^\text{27,28}\) In particular, of particular rele-
ance is the role of IL-6 in enhancing the expression of receptor
activator of nuclear factor-kB ligand (RANKL) on the sur-
face of stromal/osteoblastic cells, which in turn stimulates
osteoclast differentiation and bone resorption. Although this
process can promote bone remodeling with potential positive
effects for bone homeostasis under physiological conditions,
in RA its exaggerated and long-lasting activation induces
abnormal osteoclastogenesis, leading to osteoporosis and
bone destruction.\(^\text{27,28,32}\)

The role of IL-6 in RA

A large body of evidence from experimental and clinical stud-
ies has demonstrated the key role of IL-6 in the pathogenesis
of RA, both in promoting basic immunopathologic mechan-
isms and mediating target organ damage.\(^\text{23,33}\) In particular,
RA patients show elevated IL-6 levels in both synovial fluid
and blood, which correlate with disease activity and structural
damage progression.\(^\text{34–37}\) Moreover, IL-6-deficient mice did
not develop experimental inflammatory arthritis, both in
antigen- and collagen-induced models.\(^\text{38,39}\) Finally, selec-
tive IL-6 blockade with TCZ produces unequivocal clinical
benefits in RA patients as a result of a marked reduction in
joint involvement and systemic manifestations.\(^\text{5,40,41}\)

Autoimmune process development

RA is an autoimmune disorder driven by both T- and
B-lymphocyte activation. Increasing evidence indicates that
IL-6 actively mediates the immunologic process underlying
the disease by promoting the transition from innate to acquired
immune response as well as autoantibody production. IL-6
is essential for CD4\(^+\) T-lymphocyte differentiation to T\(_{\text{h17}}\)
cells, and it inhibits TGF-\(\beta\)-induced regulatory T-cell (Treg),
leading to an increased T\(_{\text{h17}}\)/Treg ratio that is thought to play
a major role in RA development. Moreover, IL-6 induces
B-cell differentiation through a direct action on plasmablasts,
as well as by stimulating the development of T follicular
helper cells, which secrete the B-cell differentiation factor
IL-21.\(^\text{23,33}\) Accordingly, in RA patients, IL-6 and IL-21 serum
levels are associated with increased autoantibody secre-
tion (rheumatoid factor, RF, and anti–cyclic citrullinated
protein, anti-CCP), and higher levels of markers of B-cell
activation.\(^\text{37}\) Moreover, it has been demonstrated that TCZ
treatment restored T\(_{\text{h17}}\)/Treg imbalance,\(^\text{42,43}\) reduced IL-21
expression by CD4-positive T-cells,\(^\text{44}\) and inhibited RF and
anti-CCP production.\(^\text{44,45}\)

Articular damage

Activated synovial fibroblasts and macrophages represent
a major source of IL-6 in the RA joint. The synovial fluid
also contains high levels of sIL-6R, mainly deriving from
monocytes and lymphocytes infiltrating into the synovium.
Thus, via activation of classical signaling and, particularly,
transsignaling pathway, IL-6 can target a wide range of
joint cells in the synovium, cartilage, and subchondral
bone, chiefly involved in the development of RA articular
damage (Figure 2).\(^\text{2,3,33,41}\)

By amplifying inflammatory cell infiltration, neovascu-
arization, and synoviocyte hyperplasia, IL-6 aggravates the
synovitis process and favors the formation of the inflamma-
atory vascular tissue known as “pannus”.\(^\text{8,41}\) In particular, IL-6
exerts potent stimulating effects on synovial fibroblastic cells,
which result in cell proliferation,\(^\text{46}\) and vascular endothelial
growth factor synthesis, which promotes angiogenesis.\(^\text{47}\)
Moreover, IL-6 enhances chemokine production (monocyte
chemotactic protein-1 and IL-8) from endothelial cells,
mononuclear cells, and synovial fibroblasts, as well as
adhesion molecules expression on endothelial cells, leading
to increased monocyte accumulation in the synovium.\(^\text{16,33}\)
Notably, these changes markedly reduced when IL-6 signal-
ing was inhibited by using TCZ in both experimental models
and clinical studies in RA patients.\(^\text{41}\)

Once established, synovial inflammation drives joint
structural damage by inducing cartilage degradation and
bone resorption. Also in this case, IL-6 plays a key role as
a result of specific effects on chondrocytes and bone cells
of the subchondral bone. Indeed, IL-6 targets chondro-
cytes leading to production and release of matrix metal-
loproteinases (MMP-1, MMP-3, and MMP-13), a group
of enzymes playing a crucial role in cartilage catabolism,
as well as inhibition of cartilage matrix synthesis.\(^\text{41,48}\)
Moreover, osteoclastogenesis is enhanced via stimulation of
RANKL expression on osteoblasts and synovial fibroblasts
(Figure 2).\(^\text{32,49}\) TCZ treatment reduced MMP-3 expression
and increased cartilage synthesis in IL-6-stimulated cultured
human chondrocytes, prevented proteoglycan loss in arthritic
monkeys, and improved serum levels of cartilage turnover
markers (N-terminal propeptide of Type II collagen, Type II
collagen helical peptide, MMP-3) in RA patients.\(^\text{41}\) Finally,
TCZ significantly inhibited bone erosion and joint space narrowing, along with an improvement in bone resorption markers (C-terminal cross-linking telopeptide of Type I collagen) when administered to RA subjects for 52 weeks.33,41

**Extra-articular manifestations**

Besides stimulating acute-phase protein synthesis leading to elevation of circulating markers of inflammation, particularly CRP, IL-6 significantly contributes to a number of other systemic signs and symptoms frequently observed in RA patients, including fever, malaise, fatigue and muscle weakness, sleep disturbances, anxiety, and depression.41,50 Moreover, IL-6 is actively involved in the development of anemia and accelerated CVD, which represent two among the most important extra-articular manifestations of the disease (Figure 2).

Anemia occurs in 30%–60% of patients with RA. In the majority of cases, it is characterized by decreased serum iron and transferrin saturation, along with elevated serum ferritin levels. This form, termed anemia of chronic diseases, is chiefly driven by IL-6 via induction of hepcidin synthesis by the liver (Figure 2).51,52 Hepcidin is an iron-regulator hormone mediating evolutionary mechanisms contributing to host defense by decreasing iron availability to invading pathogens. However, by inhibiting iron absorption in the small intestine and the release of recycled iron from macrophages, hepcidin also leads to reduced iron delivery to maturing erythrocytes in the bone marrow.51 The severity of anemia of chronic diseases in RA strictly correlates with IL-6 levels, while TCZ treatment induces a rapid increase in hemoglobin levels as a result of an inhibitory effect on hepcidin production.41,52

In RA patients, the prevalence of CVD is significantly increased, accounting for ~50% of premature deaths observed.3 Evidence indicates that enduring systemic inflammation plays a key role in accelerating heart disease development and progression in these patients. In this scenario, inflammatory cytokines play a pivotal role through a myriad of pathogenic mechanisms. In particular, IL-6 enhances the immunoinflammatory process underlying
atherogenesis either directly, affecting the cells of the plaque, or indirectly, promoting a number of metabolic changes, including insulin resistance, dyslipidemia, and prothrombotic/antifibrinolytic effects. This results in profound vascular changes including both endothelial dysfunction-dependent and endothelial-independent defects, in turn promoting atherosclerosis, as well as increased plaque inflammation leading to higher vulnerability to rupture and thrombosis.\(^4,4^\) Accordingly, two large genetic studies demonstrated that the IL-6R pathway is causally implicated in the development of coronary artery disease in the general population.\(^5,5^\) Moreover, a TCZ single dose administration reduced inflammatory response and myocardial injury in patients with acute myocardial infarction.\(^6^\) In addition, in RA patients, TCZ treatment decreases insulin resistance,\(^7\) improves endothelial function and arterial stiffness,\(^8,8^\) and reduces plasminogen activator inhibitor-1 serum levels.\(^9\) Furthermore, although cholesterol (total and LDL) and triglyceride levels increase, TCZ concomitantly increases HDL cholesterol with no changes in the atherogenic index, also reducing lipoprotein(a) levels, and improving HDL cholesterol efflux capacity.\(^5,5^\)

In RA patients, the risk of arrhythmic events is also significantly higher than in non-RA subjects, as indicated by the increased incidence of sudden cardiac death and atrial fibrillation. Although this is in part explained by accelerated structural heart disease, increasing evidence indicates that arrhythmogenicity in RA may be also the result of inflammation-driven nonstructural heart abnormalities of electrophysiological origin (Figure 2).\(^3,3^\) In particular, it has been demonstrated that IL-6 prolongs action potential duration in pig ventricular cells by enhancing L-type calcium current,\(^4^\) also increasing the propensity to develop atrial fibrillation in an in vitro model of rat atrial tissue.\(^5^\) Moreover, in RA patients, circulating IL-6 levels correlated with the duration of ventricular repolarization as assessed by the corrected QT interval (QTc) on electrocardiogram,\(^6^\) and TCZ therapy was associated with a rapid (within 3 months) QTc shortening, which correlated with the decrease in CRP levels.\(^5^\) Finally, a recent study on a large cohort of women with RA demonstrated that inflammation, as assessed by IL-6 circulating levels, more strongly correlated with fatal than nonfatal cardiovascular events.\(^5^\)

**Pharmacology of SRK**

SRK is a human anti-IL-6 monoclonal antibody that binds to IL-6 with high affinity and specificity. It prevents IL-6 from interacting with IL-6Rs, both the transmembrane and the soluble form, thus resulting in an inhibition of IL-6-mediated signal pathways and related biological effects.

After intravenous (IV, 0.3–10 mg/kg)\(^6^\) or subcutaneous (SC, 25–100 mg)\(^6^\) single administration of SRK in healthy subjects, maximum concentration and area under the concentration–time curve increase in an approximately dose-proportional manner. On the contrary, the clearance and half-life (estimated value 20.9 days) of the drug appeared to be independent of dose. The volume of distribution at steady state in a subject weighing 70 kg was 8.3 L, ie, \(\sim\)2 times the plasma volume, suggesting that the molecule is primarily located in the circulatory system, with limited extravascular tissue distribution. These data, considered as a whole, indicate that SRK has a linear pharmacokinetic profile (Table 1),\(^6,6^\) different from the nonlinear behavior showed by TCZ. Studies demonstrated that sex and race do not significantly affect these pharmacokinetic parameters. Conversely, to date, no studies have addressed the effect of hepatic or renal impairment on the pharmacokinetics of SRK.

Limited information also exists regarding the impact of this drug on cytochrome p450 (CYP) activity. Nevertheless, it is well documented that IL-6 induces inhibition of CYP enzymes, including CYP34, CYP2C19, CYP2C9, and CYP1A2, and available data suggest that SRK may reverse this effect. In particular, an in vivo study demonstrated that the levels of the CYP substrates midazolam, omeprazole, and warfarin reduced by 30%–35%, 37%–45%, and 18%–19%, respectively, 15 days after a single SC administration of SRK (300 mg) in patients with active RA. Notably, drug effect on CYP substrates was sustained for at least 6 weeks. As a result, drugs characterized by a narrow therapeutic range and profoundly influenced by CYP activity, such as warfarin, need to be closely monitored upon initiation or discontinuation of SRK.\(^6^\)

**SRK in RA**

In consideration of the aforementioned pivotal role played by IL-6 in the pathogenesis of RA, as well as of the large evidence of effectiveness demonstrated by TCZ in these patients in the clinical practice, in the past years marked attention has been focused on the potential of SRK as a new therapeutic tool in the treatment of RA.

To date, one Phase II clinical study was completed and published in 2014.\(^6^\) Moreover, SRK has been or is being evaluated in five Phase III studies, among which three have been already completed or have estimated completion dates in late 2016 or early 2017 (Tables 1–3).
### Table 1: Published clinical studies of sirukumab

<table>
<thead>
<tr>
<th>Author</th>
<th>Design</th>
<th>Population</th>
<th>Duration (weeks)</th>
<th>Treatment arms</th>
<th>Main findings</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xu et al[7]</td>
<td>Phase I, double-blind, placebo-controlled, ascending single-dose study</td>
<td>45 healthy subjects (7♀)</td>
<td>20</td>
<td>SRK (0.3, 1, 3, 6, or 10 mg/kg) single IV dose, or placebo</td>
<td>SRK showed linear pharmacokinetics, without sex differences. Median terminal half-life: 18.5–29.6 days. Population estimates: clearance 0.364 L/d; central volume of distribution 3.28 L; inter-compartamental clearance: 0.588 L/d; peripheral volume distribution 4.97 L. No subjects tested positive for anti-SRK antibodies.</td>
<td></td>
</tr>
<tr>
<td>Zhuang et al[8]</td>
<td>Phase I, randomized, placebo-controlled, ascending single-dose study</td>
<td>49 healthy subjects (25 Japanese, 24 Caucasian)</td>
<td>15</td>
<td>SRK (25, 50, or 100 mg) single SC dose, or placebo</td>
<td>SRK showed linear pharmacokinetics, without racial differences. Mean half-life: 15–18 days. Population estimates: clearance 0.54 L/d; volume of distribution 12.2 L. No subjects tested positive for anti-SRK antibodies.</td>
<td></td>
</tr>
<tr>
<td>Zhuang et al[9]</td>
<td>Phase I, open-label, multicenter, single-dose study</td>
<td>12 RA patients (7♀)</td>
<td>54</td>
<td>SRK 300 mg single SC dose</td>
<td>SRK reversed IL-6-mediated suppression of CYP activity in RA patients: after SRK administration, area under the plasma concentration-time curve for midazolam (CYP3A substrate), omeprazole (CYP2C19), and S-warfarin (CYP2C9) was reduced by 30%–35%, 37%–45%, and 18%–19%, respectively. The effect of SRK on CYP substrates was sustained for 6 weeks.</td>
<td></td>
</tr>
<tr>
<td>Smolen et al[10]</td>
<td>Phase II, two-part, (Part A: proof-of-concept; Part B: dose-finding), randomized, double-blind, placebo-controlled study</td>
<td>Part A: 36 RA patients (25♀)</td>
<td>Part B: 22</td>
<td>Part A: SRK 100 mg q2w SC, or placebo through week 10 with crossover treatment during weeks 12–22 Part B: SRK (100 mg q2w, 100 mg q4w, 50 mg q4w, or 25 mg q4w) SC through week 24, or placebo through week 10 with crossover to SRK 100 mg q2w (weeks 12–24)</td>
<td>The primary endpoint (ACR50 at week 12 in Part B) was achieved only with sirukumab 100 mg q2w vs placebo (26.7% vs 3.3%; P=0.026). Greater improvements in mean DAS28-CRP at week 12 were observed with sirukumab 100 mg q2w vs placebo in both Part A (2.1 vs 0.6, P&lt;0.001) and Part B (2.2 vs 1.1; P&lt;0.001). Two patients tested positive for anti-SRK antibodies.</td>
<td></td>
</tr>
<tr>
<td>Szepietowski et al[11]</td>
<td>Phase I, two-part, double-blind, placebo-controlled, multiple IV, dose ascending study</td>
<td>Part A: 33 CLE patients (21♀)</td>
<td>Part B: 15 SLE patients (13♀)</td>
<td>Part A: SRK (1, 4, or 10 mg/kg) four IV infusions q2w, or placebo Part B: SRK 10 mg/kg four IV infusions q2w, or placebo</td>
<td>SRK showed linear pharmacokinetics, with similar systemic exposure between CLE and SLE patients. Mean half-life was also comparable between CLE (16–23 days) and SLE patients (18 days). No patients tested positive for anti-SRK antibodies. CRP and serum amyloid A were suppressed from week 1 to week 14. At week 24, the median percent change in proteinuria from baseline in SRK-treated patients was 0.0% (95% Ci: -61.8, 39.6), while the placebo (n=4) patients showed a median percent increase in proteinuria of 43.3% at week 24. Nevertheless, a subset of 5 SRK-treated patients had ≥50% improvement in proteinuria through week 28. In the SRK group 47.6% of patients had ≥1 serious adverse event, mainly infections, vs 0 patients in the placebo group. Five patients discontinued the study early due to adverse events.</td>
<td></td>
</tr>
<tr>
<td>Rovin et al[12]</td>
<td>Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group, proof-of-concept study</td>
<td>25 patients with active lupus nephritis (21♀) despite immuno-suppression</td>
<td>40</td>
<td>SRK 10 mg/kg q4w IV, or placebo through week 24</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** SRK, sirukumab; CRP, C-reactive protein; RA, rheumatoid arthritis; IV, intravenously; SC, subcutaneously; CYP, cytochrome P450; DAS28-CRP, disease activity score in 28 joints using CRP, CLE, cutaneous lupus erythematosus; SLE, systemic lupus erythematosus; q2w, every 2 weeks; q4w, every 4 weeks; CI, confidence interval.
Table 2 AEs in Phase I/II trials of SRK

<table>
<thead>
<tr>
<th>Author</th>
<th>Treatment arms</th>
<th>Any AEs (at least 1)</th>
<th>Serious AEs</th>
<th>Death</th>
<th>Serious infection</th>
<th>Neoplasm</th>
<th>Injection site reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xu et al17</td>
<td>SRK (0.3, 1, 3, 6, 10 mg/kg) IV single dose</td>
<td>56%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>73%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Zhuang et al18</td>
<td>SRK (25, 50, 100 mg) SC single dose</td>
<td>61%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td>25%</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>46%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td>21%</td>
</tr>
<tr>
<td>Zhuang et al19</td>
<td>SRK 300 mg SC single dose</td>
<td>100%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td>67%</td>
</tr>
<tr>
<td>Smolen et al20</td>
<td>Part A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRK 100 mg SC q2w</td>
<td>71%</td>
<td>6%</td>
<td>6%</td>
<td>0</td>
<td>0</td>
<td>35%</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>63%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10%</td>
</tr>
<tr>
<td></td>
<td>Part B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRK (25, 50, 100 mg) SC q2w or q4w</td>
<td>86%</td>
<td>13%</td>
<td>1%</td>
<td>5%</td>
<td>1%</td>
<td>16%</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>67%</td>
<td>9%</td>
<td>0</td>
<td>3%</td>
<td>0</td>
<td>3%</td>
</tr>
<tr>
<td>Szepietowski et al21</td>
<td>Part A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRK (1, 4, 10 mg/kg) IV q2w</td>
<td>91%</td>
<td>13%</td>
<td>4%</td>
<td>0</td>
<td>4%</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>63%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Part B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRK 10 mg/kg IV q2w</td>
<td>90%</td>
<td>20%</td>
<td>0</td>
<td>10%</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>80%</td>
<td>20%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>Rovin et al22</td>
<td>SRK 10 mg/kg IV q4w</td>
<td>100%</td>
<td>48%</td>
<td>0</td>
<td>38%</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>100%</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: AEs, adverse events; SRK, sirukumab; IV, intravenously; SC, subcutaneously; q2w, every 2 weeks; q4w, every 4 weeks; NA, datum not available.

Phase II clinical study

Smolen et al20 conducted a randomized, two-part (proof-of-concept and dose-finding) Phase II study in patients with active RA despite methotrexate (MTX) therapy, with the primary objective represented by the evaluation of SRK safety and efficacy (Table 1).

In part A (proof of concept), 36 RA patients were randomly allocated to receive SC placebo or SRK 100 mg every 2 weeks (q2w) through week 10, with crossover treatment during weeks 12–22.

In part B (dose finding), 151 RA patients were randomized to receive SC SRK (100 mg q2w, 100 mg every 4 weeks (q4w), 50 mg q4w, or 25 mg q4w) for 24 weeks, or placebo through week 10, with crossover to SRK 100 mg q2w (weeks 12–24). The differences in the percentage of patients reaching an American College of Rheumatology 50 (ACR50) response and change from baseline in the 28-joint count disease activity score using CRP (DAS28-CRP) were determined.

The primary end point (ACR50 at week 12 in Part B) was achieved only with SRK 100 mg q2w vs placebo (26.7% vs 3.3%; P=0.026). Greater improvements in mean DAS28-CRP at week 12 were observed with SRK 100 mg q2w vs placebo in Parts A (2.1 vs 0.6, P<0.001) and B (2.2 vs 1.1; P<0.001). Clinical response to SRK occurred as early as week 2 and persisted through week 24 despite SRK crossover to placebo.

SRK rapidly reduced CRP to or near the limit of detection (3.0 mg/L, within 2 weeks), also maintaining these levels through at least week 24. Changes in neutrophil and platelet counts consistent with the degree of CRP suppression over time were also observed. In both parts, transient elevations in alanine transferase were reported, more commonly within 4 weeks, with levels that declined or returned to normal without interruption of dosing. Moreover, increases in lipid levels were observed in the SRK group within 2 weeks, and sustained through week 12 (part A)–24 (part B). In particular, ~35% of SRK-treated patients with normal baseline LDL levels had abnormal values (>130 mg/dL) at week 24.

From a pharmacokinetic point of view, mean half-life values ranged from 15 to 19 days, while serum SRK concentrations achieved steady state by week 12. The incidence of adverse events (AEs) was similar for SRK- and placebo-treated patients through week 12 in Part A (70.6% and 63.2%, respectively) and B (67.8% and 66.7%, respectively). Infections were the most common type of AE. Opportunistic infections were not reported, nor were gastrointestinal perforations. One death occurred, in Part B (SRK 100 mg q2w), related to brain aneurysm rupture. Injection site reactions occurred more frequently among patients receiving SRK, but in most cases they were considered mild (Table 2). Two patients (1.2%) tested positive for antibodies to SRK: neither patient had an injection site reaction. Although one patient was also positive for neutralizing anti-SRK antibodies, he remained a responder through week 30.20
Table 3  Ongoing clinical trials of SRK

<table>
<thead>
<tr>
<th>Name/number</th>
<th>Design</th>
<th>Population prior treatment</th>
<th>Treatment arms</th>
<th>Primary endpoint</th>
<th>Study status</th>
<th>Estimated completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIRROUND-D1</td>
<td>Phase III, multicenter,</td>
<td>1,670 RA patients with active disease despite DMARD</td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or SRK 50 mg SC q4w through week 104, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 104, or placebo</td>
<td>Proportion of patients with ACR20 response, and change from baseline in vdH score</td>
<td>Active, nonrecruiting</td>
<td>January 2017</td>
</tr>
<tr>
<td></td>
<td>randomized, double-blind,</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 104, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>placebo-controlled,</td>
<td></td>
<td>Group 1: adalimumab 40 mg q2w through week 52 Group 2: SRK 100 mg q2w through week 52 Group 3: SRK 50 mg q4w through week 52</td>
<td>Change from baseline in DAS28-ESR, and percentage of ACR50 response</td>
<td>Active, nonrecruiting</td>
<td>August 2016</td>
</tr>
<tr>
<td></td>
<td>parallel group study</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 23, or SRK 50 mg SC q4w through week 52, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 52, or placebo</td>
<td>Proportion of patients with ACR20 response</td>
<td>Completed</td>
<td>January 2016</td>
</tr>
<tr>
<td>SIRROUND-H2</td>
<td>Phase III, multicenter,</td>
<td>559 RA patients with active disease</td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>randomized, double-blind,</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>placebo-controlled,</td>
<td></td>
<td>Group 1: adalimumab 40 mg q2w through week 52 Group 2: SRK 100 mg q2w through week 52 Group 3: SRK 50 mg q4w through week 52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>parallel group study</td>
<td></td>
<td>Group 1: adalimumab 40 mg q2w through week 52 Group 2: SRK 100 mg q2w through week 52 Group 3: SRK 50 mg q4w through week 52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIRROUND-T3</td>
<td>Phase III, multicenter,</td>
<td>878 RA patients with active disease</td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>randomized, double-blind,</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>placebo-controlled,</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>parallel group study</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 100 mg SC q2w through week 52 Group 3: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIRROUND-M4</td>
<td>Phase III, multicenter,</td>
<td>121 RA patients with active disease unresponsive to methotrexate or sulfasalazine</td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 50 mg SC q4w through week 52, or placebo</td>
<td>Proportion of patients with AEs</td>
<td>Completed</td>
<td>March 2015</td>
</tr>
<tr>
<td></td>
<td>randomized, double-blind,</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>placebo-controlled,</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>parallel group study</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 52, or placebo Group 2: SRK 50 mg SC q4w through week 52, or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIRROUND-LTe5</td>
<td>Phase III, multicenter,</td>
<td>RA patients completing SIRROUND-D and SIRROUND-T studies</td>
<td>Group 1: SRK 100 mg SC q2w through week 156 (SIRROUND-D participants) and 208 (SIRROUND-T participants) Group 2: SRK 50 mg SC q4w through week 156 (SIRROUND-D participants) and 208 (SIRROUND-T participants)</td>
<td>Proportion of patients with cardiovascular serious AEs, malignancies, serious infections, or gastrointestinal perforations</td>
<td>Enrolling by invitation</td>
<td>April 2020</td>
</tr>
<tr>
<td></td>
<td>randomized, double-blind,</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 156 (SIRROUND-D participants) and 208 (SIRROUND-T participants) Group 2: SRK 50 mg SC q4w through week 156 (SIRROUND-D participants) and 208 (SIRROUND-T participants)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>placebo-controlled,</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 156 (SIRROUND-D participants) and 208 (SIRROUND-T participants) Group 2: SRK 50 mg SC q4w through week 156 (SIRROUND-D participants) and 208 (SIRROUND-T participants)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>parallel group study</td>
<td></td>
<td>Group 1: SRK 100 mg SC q2w through week 156 (SIRROUND-D participants) and 208 (SIRROUND-T participants) Group 2: SRK 50 mg SC q4w through week 156 (SIRROUND-D participants) and 208 (SIRROUND-T participants)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIRRESTA6</td>
<td>Phase III, multicenter,</td>
<td>Estimated enrollment of 204 GCA patients under prednisone treatment</td>
<td>SRK 100 mg q2w SC, or SRK 50 mg q4w SC through week 52 (Part A, double-blind treatment phase) and week 104 (Part B, long-term extension phase), or placebo</td>
<td>Proportion of patients in sustained remission at week 52</td>
<td>Active, recruiting</td>
<td>May 2020</td>
</tr>
<tr>
<td></td>
<td>randomized, double-blind,</td>
<td></td>
<td>SRK 100 mg q2w SC, or SRK 50 mg q4w SC through week 52 (Part A, double-blind treatment phase) and week 104 (Part B, long-term extension phase), or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>placebo-controlled,</td>
<td></td>
<td>SRK 100 mg q2w SC, or SRK 50 mg q4w SC through week 52 (Part A, double-blind treatment phase) and week 104 (Part B, long-term extension phase), or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>parallel group study</td>
<td></td>
<td>SRK 100 mg q2w SC, or SRK 50 mg q4w SC through week 52 (Part A, double-blind treatment phase) and week 104 (Part B, long-term extension phase), or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02473289</td>
<td>Phase II, multicenter,</td>
<td>Estimated enrollment of 192 patients with major depressive disorder under treatment with a monoamineergic antidepressant</td>
<td>Group 1: SRK 50 mg SC on day 1, 28, and 56 Group 2: placebo</td>
<td>Change from baseline in HDRS17 at week 12</td>
<td>Active, recruiting</td>
<td>October 2017</td>
</tr>
<tr>
<td></td>
<td>randomized, double-blind,</td>
<td></td>
<td>Group 1: SRK 50 mg SC on day 1, 28, and 56 Group 2: placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>placebo-controlled,</td>
<td></td>
<td>Group 1: SRK 50 mg SC on day 1, 28, and 56 Group 2: placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>parallel study</td>
<td></td>
<td>Group 1: SRK 50 mg SC on day 1, 28, and 56 Group 2: placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** RA, rheumatoid arthritis; SRK, sirukumab; SC, subcutaneously; q2w, every 2 weeks; q4w, every 4 weeks; ACR, American College of Rheumatology; DAS28-ESR, disease activity score in 28 joints using erythrocyte sedimentation rate; vdH, van der Heijde score; AEs, adverse events; TNF-α, tumor necrosis factor-α; HDRS17, Hamilton Depression Rating Scale; GCA, giant-cell arteritis.
Phase III clinical studies
SRK is currently being investigated in three main Phase III clinical trials for treating patients with moderate-to-severe active RA: SIRROUND-D, SIRROUND-H, and SIRROUND-T (Table 3).

SIRROUND-D (NCT01604343) is a multicenter, randomized, double-blind, placebo-controlled, parallel group study in 1,670 patients with active RA who were unresponsive to DMARDs. The primary objective was to assess the efficacy of SC SRK as measured by the reduction of the signs and symptoms of RA and inhibition of radiographic progression. Although the estimated study completion date is January 2017, preliminary results have been very recently presented (June 2016) at the Annual Congress of Rheumatology (EULAR 2016) in London, UK. Compared to placebo, both SRK 50 mg q4w and 100 mg q2w significantly reduced signs/symptoms of RA (ACR20 at week 16 and ACR50 at week 24 achieved by 26.4% vs 54.8%–53.5%, and 12.4% vs 30.2%–33.2%, respectively; \( P \leq 0.001 \)), inhibited radiographic progression, and improved health-related quality of life, showing a safety profile consistent with the known safety profile of anti-IL-6 treatment.72

SIRROUND-H (NCT02019472) is a multicenter, randomized, double-blind, parallel-group study comparing SC SRK with the anti-TNF-\( \alpha \)-monoclonal antibody adalimumab, each given as monotherapy in 559 biologic naïve patients with moderately to severely active RA who were intolerant to MTX, who were considered inappropriate for treatment with MTX, or who were unresponsive to MTX. The primary objective was to assess the efficacy of each treatment as monotherapy. The estimated study completion date is August 2016.73

SIRROUND-T (NCT01606761) is a multicenter, randomized, double-blind, placebo-controlled, parallel group study of SRK in 878 patients with active RA who were unresponsive or intolerant to anti-TNF-\( \alpha \)-agents. The primary objective was to assess the efficacy of SC SRK as measured by the reduction of the signs and symptoms of RA. The study has been completed in January 2016, but no results have been still published.74

Two additional trials include SIRROUND-M (NCT01689532), in 122 Japanese patients with moderately to severely RA who did not respond to treatment with MTX or sulfasalazine (completed in March 2015; results still not published),75 and SIRROUND-LTE (NCT01856309), the extension study for patients who complete the SIRROUND-T and SIRROUND-D studies to evaluate long-term safety and efficacy of SRK in RA (estimated completion date April 2020); (Table 3).76

SRK vs TCZ and other IL-6 inhibitors in RA
The clinical efficacy and safety shown by SRK in RA in the available clinical studies seems to be largely overlapping those reported for TCZ and other IL-6 inhibitors, regardless that the specific inhibitory mechanism is the direct targeting of the cytokine or its receptor. In fact, besides SRK, the other two anti-IL-6 monoclonal antibodies, ie, olakizumab and clazakizumab, and the one other anti-IL-6R monoclonal antibody, ie, sarilumab, have been recently evaluated in Phase II clinical studies in RA patients.77

In particular, the differences in ACR20 and ACR50 response rates between the SRK groups vs placebo at week 12 (27%–54% and 16%–23%, respectively) reported by Smolen et al70 were consistent with those observed with TCZ (week 16: 22%–33% and 3%–24%, respectively), as well as olakizumab (week 12: 32%–61% and 11%–33%, respectively), sarilumab (week 12: 3%–26% and 7%–25%, respectively), or clazakizumab (week 16: 29%–46% and 26%–35%, respectively).

Similar considerations can be done for the drug safety profile. Also in this case, incidence and severity of commonly reported AEs, including respiratory and urinary tract infections, gastrointestinal, and nervous system disorders, showed no significant differences among different IL-6 inhibitors. Moreover, opportunistic infections, tuberculosis, or gastrointestinal perforations have not been reported so far with these new drugs, although safety data from daily clinical practice should be collected. Among laboratory changes, neutropenia, transient liver enzyme elevation, and increases in lipid levels were the most commonly observed. Exact clinical consequences and mechanisms of these abnormalities remain to be elucidated, but also in this case they appear broadly comparable in terms of frequency and magnitude among the five monoclonal antibodies.77

To exert its biological effects, IL-6 needs to bind the IL-6R: only when this complex is formed, signal pathways in target cell can be activated. For this reason, it is probable that indirect, rough comparisons show similar efficacy and safety among different IL-6 inhibitors, either anti-IL-6 or anti-IL-6R antibodies. Thus, it is currently unknown whether the inhibition of IL-6 rather than IL-6R has any advantages or disadvantages. A further, intriguing step forward will be to determine whether a specific block of IL-6 transsignaling
by sgp130Fc can offer additional clinical benefits over monoclonal antibody therapy against IL-6 or IL-6R.

**SRK beyond RA**

As largely discussed in the first part of the review, IL-6 is a pleiotropic cytokine whose effects range from the activation of basic mechanisms of inflammation and immunity, critically involved in a number of systemic immuno-mediated diseases beyond RA, to the regulation of key physiological functions, including development, metabolism, and mental processes.

SRK is currently under investigation for other indications different to RA, including systemic lupus erythematosus (SLE), giant-cell arteritis (GCA), and major depressive disorder (Tables 1 and 3).

**Systemic lupus erythematosus**

Many data indicate that IL-6 is actively implicated in the pathogenesis of SLE. In particular, in SLE patients, IL-6 induces B-cell differentiation and increased production of antinuclear and anti-double-stranded DNA autoantibodies, while anti-IL-6 antibodies inhibited spontaneous polyclonal antibody production by SLE monocytes and lymphocytes in vitro. Moreover, in murine models, inhibiting IL-6 activity delayed the onset of lupus nephritis, and in lupus nephritis urine IL-6 levels increase with the severity of the renal involvement. On the basis of this rationale, two clinical studies evaluated the efficacy and/or safety of SRK administration in SLE patients. In a Phase I, randomized, double-blind, and placebo-controlled study, 46 patients with cutaneous lupus erythematosus or SLE underwent multiple SRK IV infusions (1–10 mg/kg, 4 times q2w). The drug was generally well tolerated and showed a linear pharmacokinetics as observed in previous studies in healthy subjects. Moreover, SRK suppressed CRP and serum amyloid A mean concentrations until week 14, and although the study was not designed for testing efficacy, SRK group showed a tendency to improve in the British Isles Lupus Assessment Group musculoskeletal domain score.

These findings were not confirmed in a more recent Phase II, multicenter, randomized, double-blind, and placebo-controlled study aimed at evaluating the effects of a short-term (6 months) SRK treatment (10 mg/kg q4w) in 25 patients with active lupus nephritis. In fact, at week 24, SRK did not reduce proteinuria in the majority of patients (percent change from baseline: 0.0%). Moreover, in the SRK group, ~50% of patients had ≥1 serious AE, mostly infection related, in five cases leading to early study discontinuation (Tables 1 and 2).

**Other diseases**

Two further clinical trials evaluating SRK in GCA and major depressive disorder, respectively, are currently in progress (Table 3).

GCA is a granulomatous vasculitis affecting medium- and large-sized arteries responsible for cranial symptoms (ie, headaches, jaw claudication, and visual disturbance), polymyalgia rheumatica, and constitutional manifestations. IL-6 has been linked to GCA activity, and its blockade might abrogate signs and symptoms of the disease via a Treg/T<sub>H</sub>17 cell rebalance, critically involved in the GCA pathogenesis. The Phase III study SIRRESTA (NCT02531633) is a multicenter, randomized, double-blind, placebo-controlled trial, which evaluates the efficacy and safety of SC SRK with a prespecified tapering dose of prednisone for the treatment of GCA. This approach will specifically answer whether SRK treatment can reduce the duration of steroid treatment typical in clinical practice. The study started in October 2015, and estimated completion date is May 2020.

IL-6 has been associated with major depression disorder. In particular, a recent meta-analysis showed that there was a significant elevation of IL-6 levels in the plasma of depressed patients. In addition, in a post hoc analysis of the data from the earlier reported Phase II clinical trial by Smolen et al, Hsu et al found that a significant percentage of RA patients (~25%) had prevalent depressed mood and anhedonia symptoms, which significantly improved upon SRK treatment, regardless of clinical response, but with a significant association with baseline sIL-6R levels. The specific molecular mechanism underlying the link between IL-6 and major depression disorder is unclear, but both stimulation of the activity of the hypothalamic–pituitary–adrenal axis and modulation of tryptophan and serotonin metabolism have been suggested. On this basis, a Phase II clinical trial (NCT02473289) aimed at evaluating the efficacy of SRK as adjunctive treatment to monoaminergic antidepressants in patients who have had a suboptimal response to standard therapy and a screening high sensitivity CRP ≥0.3 mg/dL started in July 2015 (estimated completion date in October 2017).

**Perspectives**

IL-6 has been implicated in the pathogenesis of many autoimmune diseases different to RA and SLE, such as systemic juvenile idiopathic arthritis, adult-onset Still’s disease, Takayasu arteritis, sarcoidosis, as well as in a wide number of other disorders, ranging from malignancies to spinal disease, allograft rejection after organ transplantation, graft-versus host disease, and CVD. Although all these conditions may
theoretically represent intriguing fields of application for SRK treatment, to date no clinical trial or preclinical study is available or in progress to test this possibility, perhaps with the only exception of CVD.

RA and atherosclerosis are chronic inflammatory diseases that share many pathological and molecular features. Indeed, having RA doubles the risk of CVD compared to non-RA subjects.\(^4\) In particular, elevated circulating IL-6 is an independent risk factor for CVD in the general population,\(^25\) and it also correlates with disease activity and progression in RA patients.\(^35,36\) On this basis, the inhibitory potential of SRK on vascular inflammation was recently evaluated in a human in vitro model of RA-associated CVD in comparison with other RA drugs including TCZ, the anti-TNF-\(\alpha\) monoclonal antibody adalimumab, and the small-molecule JAK inhibitor tofacinib. By using a human endothelial cell and smooth muscle cell coculture system in which in vivo circulating concentrations of oxidized LDL, TNF-\(\alpha\), and sIL-6R were added, and atheroprone flow conditions applied, Feaver et al.\(^89,90\) demonstrated a robust transcriptional response of inflammatory genes and oxidative stress pathways compared to control conditions. Anti-IL-6 treatment with SRK significantly improved the vascular health phenotype by significantly decreasing adhesion molecule and nuclear factor-kB gene expression, while simultaneously increasing vasculoprotective responses, such as endothelial nitric oxide synthase and krüppel-like factor expression, and promoting a contractile smooth muscle cell phenotype. Although broadly comparable, SRK was more potent than TCZ in suppressing vascular inflammation or promoting vascular health. Adalimumab showed a similar but weaker trend compared to IL-6 inhibitors, while tofacinib was not effective or exacerbated CVD pathways. These results, although preclinical, are consistent with preliminary clinical data showing improvement of endothelial function and arterial stiffness in small groups of RA patients after treatment with TCZ.\(^56,57\) and support the hypothesis that SRK-dependent IL-6 inhibition may provide vascular protection in RA, and possibly beyond. Large clinical trials are warranted to confirm this hypothesis that may open new intriguing avenues in the treatment of CVD.

**Conclusion**

The evidence to date indicates SRK as an effective and well-tolerated new therapeutic tool for patients with active RA, with some preliminary data suggesting a specific beneficial impact on relevant systemic complications associated with the disease, such as depression and CVD. Conversely, although pathophysiological considerations make plausible the hypothesis that IL-6 blockade with SRK may be also beneficial in the treatment of many diseases other than RA (either autoimmune or not), available clinical data in patients with SLE do not seem to support this view, giving rise to potentially relevant concerns about drug safety. If the large Phase III clinical trials currently in progress in patients with RA confirm the efficacy and tolerability of SRK in these patients, then in the long term, this drug could in the near future occupy a place in the treatment of the disease, potentially also opening the doors to a more extended use of SRK in a wide range of disorders in which IL-6 plays a key pathogenic role.

**Disclosure**

The authors report no conflicts of interests in this work.

**References**


